5/6/2025
Last update
5/6/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
USERS' SCORE
Moderately Good
Based on 6 Reviews
7.6
Supplement Facts
Serving Size: 1 Vegetable Capsule
Amount Per Serving
%DV
Calcium
115 mg
9%
Vitamin K2 (as menaquinone-7)
100 mcg
**
Top Medical Research Studies
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Read More
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Read More
7
VKA treatment outcomes in atrial fibrillation
Our study involved a group of 1,350 patients with valvular and nonvalvular atrial fibrillation, all receiving vitamin K antagonists (VKAs). Over about 17 months, we noted an annual incidence of 4.4% for serious events like cardiovascular death and thromboembolic occurrences.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Read More
Most Useful Reviews
9
Reduces heavy bleeding
Fine! This is my favourite jar. I take it along with a large dosage of Vit. D (over 5000 units). A pleasant bonus - it thickens the blood and stops heavy periods, so caution is advised for those with thick blood.
Read More
6
No blood clots
1 people found this helpful
This is a good form of vitamin K2, specifically MK7, and does not cause blood clots. The brand is reputable and the packaging is well designed, with capsules in a glass jar. If my review was helpful, please mark it!
Read More
7.5
Prevents vascular calcification
Vitamin K2 helps remove calcium from areas where it shouldn't accumulate, such as blood vessels, and directs it to where it's needed, like bones and teeth. The difference between vitamin K and K2 is that K is obtained from plant foods, while K2 can be synthesised by the body. However, additional sources are necessary for sufficient intake.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
- All Researches
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Read More
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Read More
8
We aimed to find the best antithrombotic regimen for patients with atrial fibrillation (AF) who recently experienced acute coronary syndrome (ACS) or had a percutaneous coronary intervention (PCI).
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
Read More
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Read More
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 6 Reviews
7.6
- All Reviews
- Positive Reviews
- Negative Reviews
9
Reduces heavy bleeding
Fine! This is my favourite jar. I take it along with a large dosage of Vit. D (over 5000 units). A pleasant bonus - it thickens the blood and stops heavy periods, so caution is advised for those with thick blood.
Read More
6
No blood clots
1 people found this helpful
This is a good form of vitamin K2, specifically MK7, and does not cause blood clots. The brand is reputable and the packaging is well designed, with capsules in a glass jar. If my review was helpful, please mark it!
Read More
7.5
Prevents vascular calcification
Vitamin K2 helps remove calcium from areas where it shouldn't accumulate, such as blood vessels, and directs it to where it's needed, like bones and teeth. The difference between vitamin K and K2 is that K is obtained from plant foods, while K2 can be synthesised by the body. However, additional sources are necessary for sufficient intake.
Read More
7.5
Joint health support
Vitamin K2 should be taken with vitamin D3. The size is convenient, and the quality by Solgar is trustworthy. I’ve had no side effects, and there's no taste. The benefits are evident, especially since it helps to cleanse blood vessels of excess calcium and improves blood clotting, contributing to our joint health.
Read More
6
Enhances arterial health
MenaQ7® MK-7, a unique, bioavailable form of Vitamin K2, plays a key role in maintaining arterial health by promoting proper calcium metabolism in blood vessels and arteries. Vitamin K2-MK7 is among the forms of fat-soluble vitamin K, found in several greens and vegetables. It is effective in regulating blood clotting.
Read More
Frequently Asked Questions
7.5
Joint health support
Vitamin K2 should be taken with vitamin D3. The size is convenient, and the quality by Solgar is trustworthy. I’ve had no side effects, and there's no taste. The benefits are evident, especially since it helps to cleanse blood vessels of excess calcium and improves blood clotting, contributing to our joint health.
4
Promotes vitamin absorption
8 people found this helpful
Working! It helps to properly deplete vitamin D. Vitamin K2 is synthesised in the intestines by bacteria, so if you have digestive problems, you may be deficient in it. This vitamin should be taken alongside vitamin D for proper absorption. Vitamin K is useful for bleeding gums and affects blood clotting, so it's wise to consult your doctor and take a coagulogram test before starting it. I can confirm that Vitamin K from Solgar works well, as it has been tested.
9
Reduces heavy bleeding
Fine! This is my favourite jar. I take it along with a large dosage of Vit. D (over 5000 units). A pleasant bonus - it thickens the blood and stops heavy periods, so caution is advised for those with thick blood.
6
Enhances arterial health
MenaQ7® MK-7, a unique, bioavailable form of Vitamin K2, plays a key role in maintaining arterial health by promoting proper calcium metabolism in blood vessels and arteries. Vitamin K2-MK7 is among the forms of fat-soluble vitamin K, found in several greens and vegetables. It is effective in regulating blood clotting.
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
7
Vitamin K's role in clot management
We examined the effectiveness of vitamin K antagonists (VKAs) in patients with antiphospholipid syndrome (APS), a condition that increases the risk of blood clots. Our focus was on how monitoring INR levels affects treatment outcomes.
In a case study with two women suffering from APS, we noted that point-of-care testing often showed misleadingly high INR results. This could lead to inappropriate dosing of VKAs and a higher chance of recurrent clots.
However, our findings suggest that by developing individualized correction factors, we could enhance the accuracy of these tests, helping improve VKA management and patient safety.
In a case study with two women suffering from APS, we noted that point-of-care testing often showed misleadingly high INR results. This could lead to inappropriate dosing of VKAs and a higher chance of recurrent clots.
However, our findings suggest that by developing individualized correction factors, we could enhance the accuracy of these tests, helping improve VKA management and patient safety.
5
DOACs and VKAs show similar effectiveness
We looked into the effectiveness and safety of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) for cerebral venous thrombosis treatment. Conducted in 65 hospitals across 23 countries, this study found that the occurrence of major bleeding or recurrent clots was similar between both treatment options.
With over 600 patients involved, we observed that only a small percentage experienced these adverse outcomes within six months. Thus, both DOACs and VKAs appear to be valid choices for treating this condition, offering new insights into patient care.
With over 600 patients involved, we observed that only a small percentage experienced these adverse outcomes within six months. Thus, both DOACs and VKAs appear to be valid choices for treating this condition, offering new insights into patient care.
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
References
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. 10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. 10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. 10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. 10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. 10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. 10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. 10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. 10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. 10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. 10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. 10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. 10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. 10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. 10.1111/apt.18474
